HRSA Gets Tough With Drug Manufacturers Bucking 340B Pricing
By The CCM Team
The federal agency that oversees the 340B Drug Pricing Program has ordered drug manufacturers to comply with 340B statutory obligations and resume discounted pricing to contract pharmacies or face penalties.
The Health Resources and Services Administration (HRSA), which oversees the federal 340B Drug Pricing Program, has directed six drug manufacturers to immediately resume providing 340B discounted pricing to contract pharmacies without restrictions, and warned that they face Civil Monetary Penalties (CMPs) if they do not do so immediately.
In letters sent May 17 to the manufacturers—AstraZeneca, Lilly USA, Novartis, Novo Nordisk, Sanofi and United Therapeutics—HRSA acting Administrator Diana Espinosa, MPP, wrote that each manufacturer “must immediately begin offering its covered outpatient drugs at the 340B ceiling price to covered entities through their contract pharmacy arrangements, regardless of whether they purchase through an in-house pharmacy.” She also noted that they must comply with 340B statutory obligations and the 340B program’s CMP final rule, and “credit or refund all covered entities for overcharges that have resulted from (the) policy.”
Read the full story in Pharmacy Practice News
Consonant Custom Media provides content marketing and storytelling for hospitals, health systems, nonprofits, foundations and others who want to make more meaningful connections with their communities of interest.
We create original content that drives profitable consumer action and is truly consonant, or in harmony, with our clients' brand values.
Clients use our original content platforms strategically, to reach specific objectives in perception management, physician relations, service line development, sales and donor development.
